Patrick Beyer compensation by year
CONMED Summary Compensation Table · all 10 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Salary | $341,625 | $392,966 | $384,710 | $415,796 | $477,334 | $537,002 | $501,460 | $548,926 | $584,833 | $891,100 |
| Bonus | $0 | $23,713 | $0 | $50,000 | $0 | $0 | $58,781 | $0 | $0 | $0 |
| Stock awards | $115,623 | $0 | $0 | $0 | $0 | $0 | $0 | $425,064 | $699,883 | $2,499,971 |
| Option awards | $480,557 | $573,990 | $852,720 | $1,158,080 | $1,254,000 | $1,978,928 | $2,789,600 | $1,274,951 | $2,099,802 | $2,499,977 |
| Non-equity incentive | $127,704 | $156,523 | $273,551 | $331,908 | $283,393 | $344,447 | $165,318 | $505,300 | $398,331 | $1,129,469 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $62,580 | $79,183 | $115,232 | $129,637 | $171,728 | $361,841 | $497,612 | $545,070 | $517,236 | $614,356 |
| Total | $1,128,089 | $1,226,375 | $1,626,213 | $2,085,421 | $2,186,455 | $3,222,218 | $4,012,771 | $3,299,311 | $4,300,085 | $7,634,873 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CONMED Corp DEF 14A filed April 7, 2026, accession 0000816956-26-000047, and prior-year filings.
How this page was built: the CONMED Corp filed document, accession 0000816956-26-000047. Every figure is read from that document and cited to the page and table it appears in. Filed April 7, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 12,411 | $503,887 | — |
| RSU | 1,403 | $56,962 | — |
| RSU | 1,284 | $52,130 | — |
| RSU | 487 | $19,772 | — |
| Option | 35,742 | — | $79.95 |
| Option | 19,328 | — | $96.16 |
| Option | 22,000 | — | $144.55 |
| Option | 16,048 | — | $70.01 |
| Option | 9,350 | — | $122.55 |
| Option | 86,355 | — | $67.35 |
Per the Outstanding Equity Awards at Fiscal Year-End table in CONMED Corp's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
CONMED’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Patrick Beyer · this page | President and Chief Executive Officer | $7,634,873 |
| Todd Garner | Executive Vice President, Finance and Chief Financial Officer | $3,297,396 |
| Hollie Foust | Executive Vice President, General Counsel and Corporate Secretary | $1,842,776 |
| Brent Lalomia | Executive Vice President, Regulatory Affairs, Quality Assurance, Clinical Affairs, and Commercial Operations | $1,662,776 |
| Peter Shagory | Executive Vice President, Strategy and Corporate Development | $1,563,789 |
Board service
CONMED board · FY2025How this board is paid
Company policy: CONMED pays directors a $70,000 cash retainer and $185,000 in Stock Options (80%) and RSUs (20%). As stated in CONMED's FY2025 proxy.
The full CONMED compensation record
free company briefThis page is one person within CONMED's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the CONMED proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order CONMED's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CONMED's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.